Patents by Inventor Joseph Roy Naemura

Joseph Roy Naemura has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules
    Patent number: 7829534
    Abstract: The present invention is a method of inhibiting islet cell transplant rejection particular, to treat diabetes, such as type-1 and type-2 diabetes, by administering to a subject an effective amount of a soluble CTLA4 mutant molecule. One example of soluble CTLA4 mutant molecule is L104EA29YIg.
    Type: Grant
    Filed: October 29, 2007
    Date of Patent: November 9, 2010
    Assignee: Bristol-Myers Squibb Company
    Inventors: Christian P. Larsen, Thomas C. Pearson, Andrew B. Adams, Robert J. Peach, Peter S. Linsley, Joseph Roy Naemura, Jurgen Bajorath
  • Methods for treating immune system diseases using a soluble CTLA4 molecule
    Patent number: 7455835
    Abstract: The present invention relates to compositions and methods for treating rheumatic disease by administering to a subject, soluble CTLA4 molecules that block endogenous B7 molecules from binding their ligands.
    Type: Grant
    Filed: July 2, 2001
    Date of Patent: November 25, 2008
    Assignee: Bristol-Myers Squibb Company
    Inventors: Robert Cohen, Robert James Peach, David Hagerty, Suzette Carr, Jean-Claude Becker, Peter S. Linsley, Joseph Roy Naemura, Jurgen Bajorath
  • Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules
    Publication number: 20080160022
    Abstract: The present invention is a method of inhibiting islet cell transplant rejection particular, to treat diabetes, such as type-1 and type-2 diabetes, by administering to a subject an effective amount of a soluble CTLA4 mutant molecule. One example of soluble CTLA4 mutant molecule is L104EA29YIg.
    Type: Application
    Filed: October 29, 2007
    Publication date: July 3, 2008
    Applicant: Bristol-Myers Squibb Company
    Inventors: Christian P. Larsen, Thomas C. Pearson, Andrew B. Adams, Robert J. Peach, Peter S. Linsley, Joseph Roy Naemura, Jurgen Bajorath
  • Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules
    Patent number: 7304033
    Abstract: The present invention is a method of inhibiting islet cell transplant rejection, particularly to treat diabetes, such as type-1 and type-2 diabetes, by administering to a subject an effective amount of a soluble CTLA4 mutant molecule. One example of a soluble CTLA4 mutant molecule is L104EA29YIg.
    Type: Grant
    Filed: May 23, 2002
    Date of Patent: December 4, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Christian P. Larsen, Thomas C. Pearson, Andrew B. Adams, Robert J. Peach, Peter S. Linsley, Joseph Roy Naemura, Jurgen Bajorath
  • Soluble CTLA4 mutant molecules
    Patent number: 7094874
    Abstract: The present invention provides soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig. The soluble CTLA4 molecules have a first amino acid sequence comprising the extracellular domain of CTLA4, where certain amino acid residues within the S25-R33 region and M97-G107 region are mutated. The mutant molecules of the invention may also include a second amino acid sequence which increases the solubility of the mutant molecule.
    Type: Grant
    Filed: May 23, 2001
    Date of Patent: August 22, 2006
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Robert J. Peach, Joseph Roy Naemura, Peter S. Linsley, Jurgen Bajorath
  • Soluble CTLA4 mutant molecules and uses thereof
    Publication number: 20040014171
    Abstract: The invention provides soluble CTLA4 mutant molecules which bind with greater avidity to the CD86 antigen than wildtype CTLA4.
    Type: Application
    Filed: January 30, 2003
    Publication date: January 22, 2004
    Applicant: Bristol-Myers Squibb Company
    Inventors: Robert James Peach, Joseph Roy Naemura, Peter S. Linsley, Jurgen Bajorath
  • SOLUBLE CTLA4 MUTANT MOLECULES AND USES THEREOF
    Publication number: 20030035816
    Abstract: The invention provides soluble CTLA4 mutant molecules which bind with greater avidity to the CD86 antigen than wildtype CTLA4.
    Type: Application
    Filed: January 28, 1998
    Publication date: February 20, 2003
    Inventors: ROBERT JAMES PEACH, JOSEPH ROY NAEMURA, PETER S. LINSLEY, JURGEN BAJORATH